Digital Pathology Market - Global Forecast to 2022

The global digital pathology market is projected to reach USD 756.1 Million by 2022 from USD 423.1 Million in 2017, at a CAGR of 12.3%. The key factors propelling the growth of this market include increasing initiatives by governments and industry players, ease of consultation, increasing adoption of digital pathology to enhance lab efficiency, rising prevalence of cancer, and growing applications of digital pathology in drug development and companion diagnostics.

Key Growth Drivers
1 Increasing Adoption of Digital Pathology to Enhance Lab Efficiency
2 Rising Prevalence of Cancer
3 Growing Applications of Digital Pathology in Drug Development and Companion Diagnostics
4 Ease of Consultation Enabled By Digital Pathology
5 Increasing Initiatives By Governments and Industry Players

Request Sample pages: https://www.marketsandmarkets.com/requestsample.asp?id=844 

On the basis of product, the market is categorized into scanners, software, communication systems, and storage systems. The software segment is projected to witness the highest growth rate in the forecast period, due to the availability of user-friendly, analytical, and advanced functions for pathology diagnosis.

In 2017, North America is expected to account for the largest share of the digital pathology market, followed by Europe. The large share of the North American region can be attributed to factors such as increasing initiatives by industry players and governments in diagnostics and the rising prevalence of chronic diseases.

 

The prominent players in the global digital pathology market are Leica Biosystems (Germany), Ventana Medical Systems (US), Hamamatsu Photonics (Japan), 3DHISTECH (Hungary), Philips (Netherlands), Apollo Enterprise Imaging (US), XIFIN (US), Visiopharm (Denmark), Corista (US), Huron Digital Pathology (Canada), Objective Pathology Services (Canada), and Indica Labs (US).